The Lancet

The Lancet Oncology is a globally renown and trusted general oncology journal with an Impact Factor of 41·6 (2023 Journal Citation Reports® Clarivate 2024) and a Scopus CiteScore of 62·1. The journal covers topics that advance clinical practice, challenge the status quo, advocate change in health policy, and tackle issues related to global oncology. Topics include but are not limited to breast cancer; endocrine system cancer; gastrointestinal cancer; genitourinary cancer; gynaecological cancer; haematological cancer; head and neck cancer; neurooncology; paediatric oncology; thoracic oncology; sarcoma; skin cancer; epidemiology, cancer prevention, and cancer control; supportive care; imaging; and health-care systems.

The Lancet Oncology also hosts events for oncologists, cancer researchers, and policymakers, and convenes many conferences, either independently or in collaboration with partners. Our next conference is The Lancet Summit: cancer control in China that will be held in Shanghai, China, from Feb 21–23, 2025.

We publish a range of article types that encompass all aspects of oncological medicine: Articles, Review, Policy Review, Personal View, Clinical Picture, Comment, Correspondence, News, and Perspectives. We also publish Series and Commissions (typically in partnership with societies, governments, NGOs, and academic centres) that aim to shape and drive positive change in clinical practice and health policy.